Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities

Overview

Journal Nanomaterials (Basel)

Date 2018 May 26

PMID 29794968

Citations 14

Authors

Yunfei Li

Brock Humphries

Chengfeng Yang

Zhishan Wang

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is the second leading cause of cancer-related death in American women and more than 90% of BC-related death is caused by metastatic BC (MBC). This review stresses the limited success of traditional therapies as well as the use of nanomedicine for treating MBC. Understanding the biological barriers of MBC that nanoparticle in vivo trafficking must overcome could provide valuable new insights for translating nanomedicine from the bench side to the bedside. A view about nanomedicine applied in BC therapy has been summarized with their present status, which is gaining attention in the clinically-applied landscape. The progressions of drug/gene delivery systems, especially the status of their preclinical or clinical trials, are also discussed. Here we highlight that the treatment of metastasis, in addition to the extensively described inhibition of primary tumor growth, is an indispensable requirement for nanomedicine. Along with more innovations in material chemistry and more progressions in biology, nanomedicine will constantly supply more exciting new approaches for targeted drug/gene delivery against MBC.

Citing Articles

A First-Principles Study of Graphene and Graphene Oxide as Potential Tamoxifen Drug Delivery Vehicles for Breast Cancer.

Wang S, Luo X ACS Omega. 2025; 10(6):5593-5600.

PMID: 39989753 PMC: 11840592. DOI: 10.1021/acsomega.4c08517.

Joining Forces: The Combined Application of Therapeutic Viruses and Nanomaterials in Cancer Therapy.

Li H, Zhu Y, Wang X, Feng Y, Qian Y, Ma Q Molecules. 2023; 28(22).

PMID: 38005401 PMC: 10674375. DOI: 10.3390/molecules28227679.

Adapting and Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care (Project ADAPT): Protocol for an Implementation Science-Based Study.

Housten A, Okere U, Colditz G, Ma C, Liu J, Harriss C JMIR Res Protoc. 2022; 11(7):e35736.

PMID: 35475732 PMC: 9361152. DOI: 10.2196/35736.

Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches.

Xia J, Ma S, Zhu X, Chen C, Zhang R, Cao Z Sci Adv. 2022; 8(6):eabj1262.

PMID: 35148178 PMC: 8836824. DOI: 10.1126/sciadv.abj1262.

Paclitaxel-based supramolecular hydrogel loaded with mifepristone for the inhibition of breast cancer metastasis.

Zhao C, Zhang C, Sun X, Guo Q, Liu J, Liu Y Cancer Sci. 2021; 113(2):733-743.

PMID: 34859546 PMC: 8819302. DOI: 10.1111/cas.15230.

References

Hudziak R, Lewis G, Winget M, Fendly B, Shepard H, Ullrich A . p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989; 9(3):1165-72. PMC: 362707. DOI: 10.1128/mcb.9.3.1165-1172.1989. View

Zhang Y, Kim W, Huang L . Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials. 2013; 34(13):3447-58. PMC: 3600638. DOI: 10.1016/j.biomaterials.2013.01.063. View

Raz A, Bucana C, Fogler W, Poste G, Fidler I . Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res. 1981; 41(2):487-94. View

OBrien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A . Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15(3):440-9. DOI: 10.1093/annonc/mdh097. View

Glinsky G, Glinsky V, Ivanova A, Hueser C . Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett. 1997; 115(2):185-93. DOI: 10.1016/s0304-3835(97)04738-1. View

Goss P, Chambers A . Does tumour dormancy offer a therapeutic target?. Nat Rev Cancer. 2010; 10(12):871-7. DOI: 10.1038/nrc2933. View

Liu Q, Li R, Qian H, Wei J, Xie L, Shen J . Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials. 2013; 34(29):7191-203. DOI: 10.1016/j.biomaterials.2013.06.004. View

Liu Y, Hu Y, Huang L . Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials. 2014; 35(9):3027-34. PMC: 3926205. DOI: 10.1016/j.biomaterials.2013.12.022. View

Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S . Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005; 11(3):263-70. DOI: 10.1038/nm1191. View

10.

Long J, Li X, Zhang F . Targeting metabolism in breast cancer: How far we can go?. World J Clin Oncol. 2016; 7(1):122-30. PMC: 4734934. DOI: 10.5306/wjco.v7.i1.122. View

11.

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

12.

Davis M, Zuckerman J, Choi C, Seligson D, Tolcher A, Alabi C . Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464(7291):1067-70. PMC: 2855406. DOI: 10.1038/nature08956. View

13.

Li Y, Jin M, Shao S, Huang W, Yang F, Chen W . Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model. BMC Cancer. 2014; 14:329. PMC: 4023534. DOI: 10.1186/1471-2407-14-329. View

14.

Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A . Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016; 11(11):986-994. PMC: 5198777. DOI: 10.1038/nnano.2016.168. View

15.

Agostini M, Knight R . miR-34: from bench to bedside. Oncotarget. 2014; 5(4):872-81. PMC: 4011589. DOI: 10.18632/oncotarget.1825. View

16.

Li Y, Humphries B, Wang Z, Lang S, Huang X, Xiao H . Complex Coacervation-Integrated Hybrid Nanoparticles Increasing Plasmid DNA Delivery Efficiency in Vivo. ACS Appl Mater Interfaces. 2016; 8(45):30735-30746. PMC: 6457453. DOI: 10.1021/acsami.6b10306. View

17.

Gradishar W, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P . Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31):7794-803. DOI: 10.1200/JCO.2005.04.937. View

18.

Um J, Kwon J, Kang C, Kim M, Ju D, Bae J . Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J Pharmacol Exp Ther. 2004; 311(3):1062-70. DOI: 10.1124/jpet.104.070938. View

19.

Nahrendorf M, Keliher E, Marinelli B, Leuschner F, Robbins C, Gerszten R . Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol. 2011; 31(4):750-7. PMC: 3060293. DOI: 10.1161/ATVBAHA.110.221499. View

20.

Friedman R . Nano dot technology enters clinical trials. J Natl Cancer Inst. 2011; 103(19):1428-9. DOI: 10.1093/jnci/djr400. View